Vimarsana
Biggest News Aggregation in the World

Page 20 - Genetics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetics Inc Today - Breaking & Trending Today

Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Call Transcript - Vimarsana News

Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Call Transcript

Matt Scalo: Good afternoon and welcome to Myriad Genetics Third Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.

Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday - Vimarsana News

Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today...

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Adtran (NASDAQ:ADTN), Alpine Immune Sciences (NASDAQ:ALPN) - Vimarsana News

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Adtran (NASDAQ:ADTN), Alpine Immune Sciences (NASDAQ:ALPN)

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $14.00 at JPMorgan Chase & Co. - Vimarsana News

Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $14.00 at JPMorgan Chase & Co.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by equities researchers at JPMorgan Chase & Co. from $17.00 to $14.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of 21.30% […]

Genetic Testing Market to Reach $40.9 Billion by 2032, Exhibiting a CAGR of 10.2% from 2023 to 2032: Allied Market Research - Vimarsana News

Genetic Testing Market to Reach $40.9 Billion by 2032, Exhibiting a CAGR of 10.2% from 2023 to 2032: Allied Market Research

/PRNewswire/ -- Allied Market Research published a report, titled, "Genetic Testing Market by Type (Predictive & Pre-Symptomatic Testing, Carrier Testing,...